In 1955, Lawrence and Sladden wrote an article on the value of physiotherapy in rheumatic diseases. As an introduction to their article they wrote: “In assessing the value of a method of treatment for rheumatic diseases the problem may be approached from 2 different angles: (1) whether the remedy relieves the pain and (2) whether it hastens recovery or renders it more complete.” This statement reflected the mainstay of the management of patients with ankylosing spondylitis (AS) for many years. Using a time machine, we can move from the mid-1950s to the third millennium when the ASsessment of SpondyloArthritis International Society (ASAS) proposed evidence based recommendations to guide the physician in the management of AS. In fact, although the use of anti-tumor necrosis factor-α treatment in AS patients must be considered a revolution in the treatment strategy of AS, the ASAS strengthened support for the approach that optimal management of AS requires a combination of non-pharmacological and pharmacological treatments. Indeed, rehabilitation is still considered one of the main treatment strategies, most of the time showing beneficial effects; and non-pharmacological therapy (including education, exercise, and physiotherapy) was included in the recommendations for AS management by the ASAS working group/EULAR. In the first update of these recommendations, it has been emphasized that regular exercise and patient education are the cornerstone of non-pharmacological treatment of AS and that supervised exercises are more effective than home exercises.

However, even considering the important role of rehabilitation, at least 2 main issues are still being addressed: (1) What strong evidence exists of the type of physical therapy/rehabilitation that is most effective in AS patients, and what is the duration of the positive effects of this treatment? In other words, how long does the positive effect last? (2) In the biological era is rehabilitation still worth considering for patients with AS?

To address the first issue we can state that physiotherapy interventions for AS have been shown to be an important part of management of the disease, being useful with a tendency to be more effective when done as a supervised outpatient group. The most recent reviews on physiotherapy interventions confirmed this treatment strategy, also indicating that exercise performed by patients under supervision was beneficial for spinal mobility when compared to the home exercise regimen, but suggested that further research was essential to delineate which exercise protocols should be recommended in the management of AS patients. Moreover, Nghiem, et al and Elyan, et al in their reviews on the rehabilitation of AS conclude, on the basis of a few published articles, that exercise should remain a mainstay of AS treatment complementing medical therapy, but that there is a need for a standardized approach to assess its real role.

A few years ago, a Korean group showed that a home-based daily exercise program increased joint mobility and functional capacity, and decreased pain and depression in AS patients. They concluded that home based exercise might be an effective intervention for the disease. To estimate the duration of positive effects of physiotherapy, again, there are no clear results. In fact, on the basis of previous results, various other studies showed that inpatient intensive rehabilitation is effective in inducing short term improvement in spinal mobility, but doubts remain about sustained improvement after long periods. Some data showed that patients with AS experienced progressive loss of movement independent of the duration of the disease and of the reported frequency of unsupervised exercise.

We showed the effectiveness of inpatient rehabilitation assessed by ASAS response criteria and this was quite a novelty using a combined index to measure the real role of rehabilitation. Indeed and interestingly, the effectiveness of intensive inpatient rehabilitation declined over time, suggesting that this therapeutic approach, per se, is not effective enough to control the disease. However, to better measure the effectiveness of rehabilitation, it would be advisable to use the ASAS response criteria in rehabilitation settings. These contradictory results may be due to methodological differences such as patient selection and physiotherapy regimen. All these results showed, clearly, that any rehabilitation program only plays a partial role in the treatment of the disease and fails to completely address the management of AS patients.

To address the second point on the possible role of rehabilitation in the era of biologics, we would consider only a combined approach (biological agents and rehabilitation). The concept of combination treatment has gained some prominence in the last few years and, at present, a few papers showed the synergistic effect of biological agents and rehabilitation. In one study designed by us, etanercept and intensive inpatient rehabilitation was used for the management of active AS, indicating that combination treatment seemed to be more effective than a simple rehabilitation program. A possible explanation for the good results obtained was that the tumor necrosis factor-α (TNF) antagonist, acting on inflammation...
and reducing fatigue, improved the effectiveness of a rehabilitation program, resulting in better functional status, better quality of life, and better perception of benefits obtained from the rehabilitation. Similar results were obtained by another study, in which an occupational treatment in combination with biological agents was beneficial, with synergistic effects on pain, function, and disability when compared to the control group treated with simple occupational therapy. Moreover, the study also showed that occupational therapy could be effective when associated with powerful biologic medications, also being a useful way to maintain and improve health status of AS patients when the disease is stable and well controlled with the drugs. Other authors showed that a combination of anti-TNF-α agents and rehabilitation can improve the benefit perceived by the AS patients when doing physiotherapy. Thus, there is a strong body of evidence that rehabilitation can improve the effects of anti-TNF-α agents.

In this issue of The Journal Masiero, et al show results of a randomized study on rehabilitation in AS patients with clinically stabilized disease on anti-TNF-α treatment. The authors showed promising results with an improvement of all outcome measures, including Bath Ankylosing Spondylitis Activity Index and some anthropometric indexes. The possible explanation for these results could be partly related to the concomitant biological treatment and partly to the good level of patients’ motivation in following the rehabilitation program. Indeed the study, innovative to some extent, also showed a positive effect of rehabilitation in the outcome measures, which was superior to those obtained from the previous course of biological therapy alone. This, in turn, could support the concept of combination treatment, but this does need more confirmation from other studies, such as multicenter randomized trials measuring outcome by a widely and accepted composite index (i.e., ASAS response criteria). Alternatively, the message could be that rehabilitation per se is the most effective treatment in AS patients.

We are pursuing the concept of a combination treatment as a way of better management of this fascinating and challenging disease. Even if the modality of combination is not yet clear, we hypothesize that adding rehabilitation to biological therapy could increase its effectiveness and/or prevent a possible treatment failure.

REFERENCES


ENNIO LUBRANO, MD, PhD, Senior Lecturer, Academic Rheumatology Unit, Department of Health Sciences, University of Molise, Campobasso; SALVATORE D’ANGELO, MD, Researcher, Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera; Department of Health Sciences, University of Molise, Campobasso; ANTONIO SPADARO, MD, Associate Professor, Dipartimento di Medicina Interna e Specialità Mediche, “Sapienza” Università di Roma, Rome; CARLO PALAZZI, MD, Senior Investigator, IGNAZIO OLIVIERI, MD, Head; Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy.

Address correspondence to Dr. Olivieri.
E-mail: ignazioolivieri@tiscalinet.it

The Journal of Rheumatology 2011; 38:7; doi:10.3899/jrheum.110362


J Rheumatol 2011;38:1228–30; doi:10.3899/jrheum.110362